Press Releases

10/27/2022

Tempus Announces Real-World Data-Driven Program to Accelerate Precision Oncology Research

Tempus, a leader in artificial intelligence and precision medicine, today announced Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes a number of medical centers that are leveraging the program to advance its research, including Allegheny Health Network...

10/25/2022

Tempus Announces Dr. Kate Sasser as Chief Scientific Officer

Tempus, a leader in artificial intelligence and precision medicine, today announced that Kate Sasser, PhD, is joining the company as its Chief Scientific Officer. Dr. Sasser brings over twenty year’s experience in translational research, precision medicine, data science, and drug discovery and development across the biotech and pharmaceutical i...

10/20/2022

Tempus Announces $275 Million in Funding

Tempus, a leader in artificial intelligence and precision medicine, today announced additional funding of approximately $275 million through a combination of equity from existing investors, which Tempus sold at the same price per share as its previous fundraising round, and debt financing from funds managed by Ares Management. In total, Tempu...

10/18/2022

GSK Announces Expanded Collaboration with Tempus in Precision Medicine to Accelerate R&D

Collaboration leverages one of world’s largest sources of de-identified patient data to accelerate drug discovery, initially in oncology Access will enable GSK to improve clinical trial design, speed up enrollment and identify drug targets GSK plc (LSE/NYSE: GSK) and Tempus, a US-based precision me...

10/06/2022

Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics

Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with Kartos Therapeutics, a clinical stage biopharmaceutical company, in support of its ongoing Phase II study of navtemadlin (KRT-232). Tempus’ CDx test, which will be developed on Tempus’ xT platform,...

09/20/2022

Tempus Announces Collaboration with the Children’s Oncology Group to Expand Access to Genomic Testing for Pediatric Cancer Patients

Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with the Children’s Oncology Group (COG) – a clinical trials group, supported by the National Cancer Institute (NCI), devoted exclusively to childhood, adolescent and young adult cancer research – to assist with their Pediatric MATCH Screening Trial...

09/09/2022

Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022

Tempus, a leader in artificial intelligence and precision medicine, today announced three abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2022, which convenes in Paris, France from September 9-13, 2022. Tempus is presenting all three abstracts, including one oral presentation and two poster presentations. ...

06/16/2022

Tempus Announces Research Collaboration with Intermountain Healthcare to Advance Precision Oncology Research

Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Intermountain Healthcare, a Utah-based, nonprofit healthcare system, which leverages genomic testing and data analytics to advance research intended to improve outcomes for cancer patients. Intermountain Healthcare is leveraging Tempus’ solid tumor/normal genomic test, xT, to generate w...

06/09/2022

Genomic Sequencing

Tempus Announces Sequencing Collaboration with Lilly to Expand Access to Genomic Testing

Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration sponsored by Eli Lilly and Company designed to provide broader access to genomic testing to patients with advanced/metastatic non-small cell lung cancer (NSCLC). Leveraging Tempus tests, this collaboration is intended to help physicians understand th...

06/07/2022

Tempus CE Marks Its Broad-Panel Genomic Sequencing and Algorithmic Diagnostic Tests

Tempus, a leader in artificial intelligence and precision medicine, today announced that it has CE marked a collection of its broad-panel genomic sequencing assays and predictive algorithm laboratory-developed tests. Alongside xT, its primary broad-panel, next-generation sequencing assay, already available on the market, additional Tempus CE marked tests are now...

NEWS

Media Coverage

Additional Partnerships